Long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: Efficacy and safety

International Journal of COPD

Volumn 3, Issue 4, 2008, Pages 521-529

  Rossi, Andrea ^a   Khirani, Sonia ^a   Cazzola, Mario ^b  

^a Bergamo Hospital   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

COPD; Efficacy; LABA; Safety

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; LONG ACTING DRUG; PLACEBO; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; OXYGEN;

BRONCHODILATATION; BRONCHUS MUSCLE; BRONCHUS SECRETION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERINFLATION; HYPOKALEMIA; MUCUS SECRETION; QUALITY OF LIFE; REVIEW; SMOOTH MUSCLE RELAXATION; AIRWAY RESISTANCE; ANIMAL; BLOOD; CARDIOVASCULAR SYSTEM; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; INHALATIONAL DRUG ADMINISTRATION; LUNG GAS EXCHANGE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AIRWAY RESISTANCE; ANIMALS; BRONCHODILATOR AGENTS; CARDIOVASCULAR SYSTEM; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; OXYGEN; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY GAS EXCHANGE; RECEPTORS, ADRENERGIC, BETA-2; TREATMENT OUTCOME;

EID: 60249085056     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Aaron SD, Vandemheen KL, Fergusson D, et al. 2007. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. Ann Inter Med, 146:545-55.
2. American Thoracic Society. 1995. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 165:838-44.
3. Anthonisen NR, Connett JE, Kiley JP, et al. 1994. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilar on the rate of decline of FEV1. The Lung Health Study. JAMA, 23:241-49.
4. Anthonisen NR, Skeans MA, Wise RA, et al. 2005. The effect of a smoking cessation intervention on 14.5-year mortality. Ann Inter Med, 142:233-39.
5. Barnes PJ. 2004. Small Airways in COPD. N Engl J Med, 350:2635-37.
6. British Thoracic Society. 2004. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax, 59 (Suppl 1):1-232.
7. Calverley PMA, Anderson JA, Celli BR, et al. 2007. Salmeterol and fluticasone propionate and survival in chronic obstructive Pulmonary disease. N Engl J Med, 356:775-89.
8. Calverley PM, Boonsawat W, Cseke Z, et al. 2003a. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J, 22:912-19.
9. Calverley PMA, Koulouris NG. 2005. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J, 25:186-99.
10. 2-agonists) study group, et al. 2003b. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet, 361:449-56.
11. Cazzola M, Andò F, Santus P, et al. 2007a. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther, 20:556-61.
12. 2-agonists and corticosteroids in stable COPD. Chest, 126:220-37.
13. Cazzola M, Di Marco F, Santus P, et al. 2004. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther, 17:35-39.
14. 2-agonists in the prevention of exacerbation in COPD. Int J Chron Obstruct Pulmon Dis, 1:345-54.
15. Cazzola M, Imperatore F, Salzillo A, et al. 1998. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest, 114:411-15.
16. 2-agonists on pulmonary artery pressure in COPD patients. Pulm Pharmacol Ther, 20:258-64.
17. Cazzola M, Matera MG. 2006. The effective treatment of COPD: Anticholinergics and what else? Drug Discov Today: Ther Strat, 3:277-86.
18. Cazzola M, Matera MG. 2007. The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: A pilot study. Respir Med, 101:957-62.
19. 2-adrenoceptor agonists. cardiovascular safety in patients with obstructive lung disease. Drugs, 65:1595-610.
20. Cazzola M, Noschese P, De Michele F, et al. 2006. Effect of formoterol/ budesonide combination on arterial blood gases in patients with acute exacerbation of COPD. Respir Med, 100:212-17.
21. Celli BR, Cole CG, Marin JM, et al. 2004. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med, 350:1005-12.
22. Celli BR, MacNee W, ATS/ERS Task Force. 2004. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 23:932-46.
23. Centanni S, Di Marco F. 2005. Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother, 6:2525-34.
24. Cooper CB. 2006. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med, 119:S21-S31.
25. Cooper CB, Tashkin DP. 2005. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ, 330:640-44.
26. Cosio M, Ghezzo H, Hogg JC, et al. 1978. The relations between structural changes in small airways and pulmonary function tests. N Engl J Med, 298:1277-81.
27. Di Marco F, Milic-Emili J, Boveri B, et al. 2003. Effect of inhaled bronchodilators on inspiratory capacity and dysnoea at rest in COPD. Eur Respir J, 21:86-94.
28. Diaz O, Villafranca C, Ghezzo H, et al. 2000. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J, 16:269-75.
29. Gayan-Ramirez G, Koulouris N, Roca J, et al. 2006. Respiratory and skeletal muscles in chronic obstructive pulmonary disease. Eur Respir Mon, 38:201-23.
30. Hanania NA, Sharafkhaneh A, Barber R, et al. 2002. β-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med, 165:1353-8.
31. Hogg JC. 2004. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet, 364:709-21.
32. Hogg JC, Chu F, Utokaparch S, et al. 2004. The nature of small airway obstruction in chronic obstructive pulmonary disease. N Engl J Med, 350:2645-53.
33. Hogg JC, Macklem PT, Thurlbeck WM. 1968. Site and nature of airways obstruction in chronic obstructive lung disease. N Engl J Med, 278:1355-60.
34. Kottakis J, Della Cioppa G, Creemers J, et al. 2002. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD. Results of a randomized, double-blind clinical study. Can Respir J, 9:107-15.
35. 2-agonist. Respir Med, 95:S7-S11.
36. Macklem PT. 1998a. The mechanics of breathing. Am J Respir Crit Care Med, 157:S88-S94.
37. Macklem PT. 1998b. The physiology of small airways. Am J Respir Crit Care Med, 157:S181-S83.
38. Man SFP, McAlister FA, Anthonisen NR, et al. 2003. Contemporary management of chronic obstructive pulmonary disease. JAMA, 290:2313-16.
39. Man WDC, Mustfa N, Nikoletou D, et al. 2004. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax, 59:471-76.
40. Matera MG, Sanduzzi A, Ponticiello A, et al. 2005. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses. Respiration, 72:466-70.
41. Murray DR, Prabhu SD, Chandrasekar B. 2000. Chronic β-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation, 101:2338-41.
42. Ng TM, Munger MA, Lombatri WL, et al. 2002. Chronically inhaled salmeterol improves pulmonary function in heart failure. J Cardiovasc Pharmacol, 40:140-45.
43. O'Donnell DE, Lam M, Webb KA. 2001. Dynamic hyperinflaction and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 164:770-77.
44. O'Donnell DE, Voduc N, Fitzpatrick M, et al. 2004. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J, 24:86-94.
45. Pauwels RA, Buist AS, Calverley PMA, et al. 2001. Global strategy for the diagnosis, management and prevention of chronich obstructive pulmonary disease. Am J Respir Crit Care Med, 163:1256-76.
46. Petty TL. 2006. The history of COPD. Int J Chron Obstruct Pulmon Dis, 1:3-14.
47. Qaseem A, Snow V, Shekelle P, et al. 2007. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Inter Med, 147:633-38.
48. Rabe KF. 2007. Treating COPD - The TORCH Trial, P values, and the Dodo. N Engl J Med, 356:851-54.
49. Rabe KF, Hurd SS, Anzueto A, et al. 2007. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 176:532-55.
50. Reisner C, Funck-Brentano C, Fischer T, et al. 2003. Cardiovascular safety of salmeterol in patients with COPD. Chest, 123:1817-24.
51. Rennard SI, Calverley PMA. 2006. Bronchodilators in chronic obstructive pulmonary disease. Eur Respir Mon, 38:266-80.
52. Rogers DF. 2005. Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options. Pulm Pharmacol Ther, 18:1-8.
53. Rossi A, Kristufek P, Levine BE, et al. 2002. Comparison of the efficacy, tolerability and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest, 121:1058-69.
54. Rossi A, Polese G, Brandi G. 1991. Dynamic Hyperinflation. In: Marini JJ and Roussos C (eds). Ventilatory Failure. Berlin: Springer-Verlag. p 199-218.
55. Sakamaki F, Satoh T, Nagaya N, et al. 1999. Abnormality of left ventricular sympathetic nervous function assessed by (123)I-metaiodobenzylguanidine imaging in patients with COPD. Chest, 116:1575-81.
56. Salpeter SR, Buckley NS, Ormiston TM, et al. 2006a. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Inter Med, 144:904-12.
57. Salpeter SR, Buckley NS, Salpeter EE. 2006b. Meta-Analysis: Anticholinergic, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med, 21:1011-19.
58. Salpeter SR, Ormiston TM, Salpeter EE. 2004. Cardiovascular effects of β-agonists in patients with asthma and COPD. Chest, 125:2309-21.
59. 2-agonists. Respir Med, 101:1798-803.
60. Siafakas NM, Vermeire P, Pride NB, et al. 1995. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J, 8:1398-420.
61. Sin DD, McAlister FA, Man SFP, et al. 2003. Contemporary management of chronic obstructive pulmonary disease. JAMA, 290:2301-12.
62. Stewart AG, Waterhouse JC, Howard P. 1995. The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD. Respir Med, 89:79-84.
63. Sutherland ER, Cherniack RM. 2004. Management of chronic obstructive pulmonary disease. N Engl J Med, 350:2689-97.
64. Szafranski W, Cukier A, Ramirez R, et al. 2003. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J, 21:74-81.
65. Tashkin DP, Cooper GB. 2004. The role of long-acting bronchodilators in the management of stable COPD. Chest, 125:249-59.
66. 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified? Curr Opin Pharmacol, 3:270-6.
67. The TORCH Study Group. 2004. The TORCH (Towards a Revolution in COPD Health) survival study protocol. Eur Respir J, 24:206-10.
68. Van Noord JA, Aumann JL, Janssens E, et al. 2005. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J, 26:214-22.
69. Van Noord JA, Aumann JL, Janssens E, et al. 2006. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest, 129:509-17.
70. Wagner PD, Dantzker DR, Lacovoni VE, et al. 19 78. Ventilation-perfusion inequality in asymptomatic asthma. Am Rev Respir Dis, 118:511-24.
71. Zimmer G, Dahinten A, Fitzner A, et al. 2000. β-Agonistic bronchodilators: comparison of dose/response in working rat hearts. Chest, 117:519-29.